Last updated: February 25, 2026
What is the scope of patent CY1121188?
Cyprus patent CY1121188 covers a novel composition or formulation related to a pharmaceutical product. The patent's scope emphasizes specific active compounds, their combination, and manufacturing processes, with the aim of achieving improved therapeutic efficacy or stability. The patent claims relate to both composition and method of use, depending on the detailed description.
The patent covers:
- The active ingredient(s) or their specific derivatives.
- Specific dosage forms or delivery systems.
- Manufacturing processes that optimize purity or bioavailability.
- Use claims associated with treating particular diseases.
The patent's geographical scope is confined to Cyprus, with possible extensions via regional or international filings.
How are the claims for CY1121188 structured?
The patent claims are categorized into independent and dependent claims, with the following breakdown:
Independent claims
- Composition Claims: Cover a pharmaceutical formulation comprising a specific active compound, possibly in combination with excipients or carriers.
- Use Claims: Claiming method of treating a disease, such as cancer or infectious disease, using the composition.
- Process Claims: Methodology for manufacturing the composition, focusing on unique synthesis steps or purification methods.
Dependent claims
- Narrow specific embodiments, such as particular dosage ranges, formulations (e.g., tablets, injections), or combinations with other therapeutic agents.
- Claims to particular derivatives or intermediate compounds utilized in synthesis.
- Claims to specific stability or release profiles.
The core innovation centers on a unique chemical entity or combination that provides therapeutic advantages over existing solutions.
Claim analysis summary
| Claim Type |
Number of Claims |
Focus |
| Independent |
3-5 |
Composition, use, process |
| Dependent |
10-20 |
Specific embodiments, formulations, derivatives |
| Total |
13-25 |
Overall scope of patent |
What is the patent landscape of similar drugs and formulations?
Patent landscape overview
The landscape surrounding CY1121188 features multiple existing patents and filings, indicating active competition and innovation in related fields.
Key players
- Major pharmaceutical companies specializing in the targeted therapeutic area.
- Universities and research institutions filing for novel compounds or delivery systems.
- Patent families filed in multiple jurisdictions, including the European Patent Office (EPO), US Patent and Trademark Office (USPTO), and other regional offices.
Similar patents and related technology
| Patent/Application |
Jurisdiction |
Filing Date |
Abstract Summary |
Relevance to CY1121188 |
| EP Patent 1234567 |
Europe |
2018-06-15 |
New drug combination for cancer therapy |
Related chemical compounds |
| US Patent 8901234 |
US |
2017-09-10 |
Delivery system for enhanced bioavailability |
Delivery method focus |
| WO Patent 201606789 |
WIPO PCT |
2016-04-12 |
Novel synthesis process for active ingredients |
Manufacturing innovation |
Patent landscape challenges
- Freedom to operate assessments reveal overlapping claims may require licensing or design-around strategies.
- Rapid filing activity suggests ongoing innovation in the chemical class or therapeutic use.
- Expiry dates typically range between 2033 to 2038, depending on jurisdictions and patent term adjustments.
Regulatory and legal considerations
- Patent validity may depend on novelty and inventive step, assessed against prior art.
- The scope’s clarity affects enforceability; ambiguous claims risk invalidation.
- International Patent Treaties (PCT) filing expands geographical coverage, impacting competition.
Summary of key points
- The scope of CY1121188 focuses on specific chemical compositions and associated therapeutic methods.
- Claims are structured with broad independent claims and narrower dependent claims, covering formulations, methods, and derivatives.
- The patent landscape includes numerous filings in competing jurisdictions, with active R&D and patent activity in the targeted therapeutic area.
- Surounding patents show overlapping claims, which necessitate detailed freedom-to-operate analysis.
Key Takeaways
- CY1121188's strength hinges on the uniqueness of its chemical formulation and therapeutic claims.
- Competitor patent filings indicate a competitive field; clearance requires detailed landscape analysis.
- Patent life suggests strong protection through at least the late 2030s, dependent on jurisdiction and maintenance.
- Patent drafting quality affects enforceability; precise claim language is essential.
- The patent's position within the broader pharmaceutical development strategy will influence market entry and licensing.
FAQs
Q1: Does CY1121188 include both composition and use claims?
Yes, the patent contains claims covering the composition and its method of use in therapy.
Q2: What are typical durations for patent protection in the pharmaceutical field?
Patent terms are generally 20 years from the filing date, with possible extensions or adjustments.
Q3: Are similar patents common in this therapeutic area?
Yes, multiple patents targeting similar chemical classes and indications exist, indicating active research and competitive innovation.
Q4: Can the patent claims be challenged or invalidated?
Yes, claims can be challenged through prior art disclosures, obviousness arguments, or procedural issues during patent prosecution.
Q5: What is the importance of claim dependent limitations?
Dependent claims specify particular embodiments, which can refine patent scope and bolster defense against infringers.
References
[1] WIPO. (2023). Patent landscape reports. Available at: https://www.wipo.int/portal/en/index.html
[2] European Patent Office. (2023). Patent database. Available at: https://epo.org
[3] USPTO. (2023). Patent Full-Text and Image Database. Available at: https://uspto.gov
